ArticleMicrobiology spectrum2023
Phenotypic Characterization and Heterogeneity among Modern Clinical Isolates of Acinetobacter baumannii.
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Data-driven Atlas ofFrontiers in cellular and infection microbiology · 2026Pooled it
- Lineage-specific loss of the type VI secretion system inAntimicrobial agents and chemotherapy · 2026Article
- Contributions of plasmid p1AB5075-encoded antibiotic resistance genes to multidrug resistance ofJournal of medical microbiology · 2026Article
- Redefining Antimicrobial Resistance inInternational journal of molecular sciences · 2026Review
- Network-level divergence in cyclic di-GMP signalling drives ecological versatility in Acinetobacter baumannii.NPJ biofilms and microbiomes · 2026Article
- Phenotype-Genotype Discordance in Antimicrobial Resistance ofPathogens (Basel, Switzerland) · 2026Review
- Combinations of colistin and bacteriocins prevent the selection of colistin resistance in Acinetobacter baumannii.Communications biology · 2026Article
- Multidrug resistant Acinetobacter baumannii shows epidemiology and transmission patterns in a China tertiary hospital ICU.Scientific reports · 2026Article
- Loss of capsule confers a growth advantage toMicrobiology spectrum · 2026Article
- Benefits and costs of a hypercapsule and the mechanism of its loss in a clinical isolate ofmBio · 2026Article
- Nutrient-driven small-colony variants as an adaptive outcome in Carbapenem-resistantCurrent research in microbial sciences · 2026Article
- Green-synthesized ZnO-MnO nanocomposite as a potent antimicrobial and antibiofilm agent: protein leakage mechanism and synergistic interaction with cefotaxime.Frontiers in microbiology · 2026Article
- Clonal lineage and biofilm growth shape cefiderocol activity inFrontiers in cellular and infection microbiology · 2026Article
- Emerging virulent clones of community-onset Acinetobacter baumannii in Taiwan.Tropical medicine and health · 2025Article
- Analysis of variations in cell envelope subproteome and cell length in Acinetobacter baumannii ATCC 19606International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Antivirulence drugs against Acinetobacter baumannii: where do they stand?World journal of microbiology & biotechnology · 2025Review
- Subinhibitory Concentrations of Oxacillin Alter Motility, Biofilm Production, and Transformation Capability of the Oxacillinase-Producing Acinetobacter baumannii.Current microbiology · 2025Article
- Acinetobacter phages use distinct strategies to breach the capsule barrier.PLoS pathogens · 2025Article
- Spontaneous Emergence of Cefiderocol Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- Inter- and intra-bacterial strain diversity remains the "elephant in the (living) room".npj antimicrobials and resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is an opportunistic pathogenic bacterium prioritized by WHO and CDC because of its increasing antibiotic resistance. Heterogeneity among strains represents the hallmark of A. baumannii bacteria. We wondered to what extent extensively used strains, so-called reference strains, reflect the dynamic nature and intrinsic heterogeneity of these bacteria. We analyzed multiple phenotypic traits of 43 nonredundant, modern, and multidrug-resistant, extensively drug-resistant, and pandrug-resistant clinical isolates and broadly used strains of A. baumannii. Comparison of these isolates at the genetic and phenotypic levels confirmed a high degree of heterogeneity. Importantly, we observed that a significant portion of modern clinical isolates strongly differs from several historically established strains in the light of colony morphology, cellular density, capsule production, natural transformability, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.